A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device for Prevention of Haemorrhagic Fever With Renal Syndrome
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jul 2019
Price : $35 *
At a glance
- Drugs PWRG-HTN-M(co)/pWRG-PUUV-M(s2) (Primary)
- Indications Hantaan virus infections; Puumala virus infections; Viral haemorrhagic fevers
- Focus Pharmacodynamics
- 18 Mar 2019 Planned End Date changed from 1 Mar 2019 to 31 Jul 2019.
- 02 May 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.